Can we finally treat joint pain without trading relief for risk? AlzeCure’s new ACD137 data hints at a shift in osteoarthritis care.
What if treating chronic joint pain didn’t require choosing between effectiveness and long-term harm? That question is at the core of a new scientific publication from Swedish biotech company AlzeCure Pharma, which has unveiled preclinical data on its lead pain candidate ACD137, a compound designed to target osteoarthritis pain through a non-opioid pathway [1].
The findings, published in the Scandinavian Journal of Pain, are not a finished therapy. Instead, they sketch a possible rethinking of how pain itself is managed at a biological level. For osteoarthritis, a condition affecting hundreds of millions globally, that shift matters more than it may first appear.
To understand ACD137, it helps to step away from the lab language for a moment. Pain in osteoarthritis isn’t just “wear and tear.” It’s more like a faulty alarm system that keeps ringing even when the original trigger has long passed. One of the biological pathways involved in that alarm system is NGF (nerve growth factor), which activates a receptor called TrkA.
ACD137 works by selectively modulating that TrkA receptor, essentially softening the signal rather than shutting down the entire system. Think of it like adjusting the sensitivity of a smoke detector so it stops going off every time you make toast.
The study describes ACD137 as highly selective and potent in preclinical models, meaning it interacts strongly with its intended target while largely avoiding others, a key factor in reducing unwanted side effects [2].
What makes the findings stand out isn’t only pain reduction, but what happened alongside it. In animal models, ACD137 didn’t just reduce pain behaviors. It also showed signs of protecting the knee joint from further deterioration, something researchers did not observe with an anti-NGF antibody used as a comparator in the study.
Most current pain treatments focus on symptom control. They quiet the alarm, but they don’t necessarily address what is causing the system to degrade in the first place. A therapy that might also slow that deterioration begins to blur the line between symptom relief and disease modification. It is early data, yes, but directionally, it matters.
Pain drug development has had a complicated history with the NGF pathway. Past therapies like tanezumab showed strong pain relief in clinical trials but raised concerns about joint safety, including rapidly progressing osteoarthritis in some patients. That history has made many developers cautious.
ACD137, however, represents a different strategy: instead of broadly blocking NGF activity, it fine-tunes signaling through TrkA.
In the study, the compound showed strong analgesic effects across multiple pain models, including neuropathic pain and osteoarthritis-like conditions. In comparative testing, its pain-relieving effect was reported to be similar to that of established treatments used in the study models.
For researchers, the key question is no longer just “does it work?” but “can it work safely over time?” That is where selectivity becomes more than a technical detail; it becomes the difference between a viable therapy and another cautionary tale.
The urgency behind this research is not abstract. “There is a significant and growing interest in our TrkA-NAM program among external stakeholders, especially since the mechanism of action has not shown the side effects and addiction problems observed with opioids. In addition, the medical need is very large and growing,” said Martin Jönsson, CEO of AlzeCure Pharma.
The need is staggering. The company cites estimates suggesting more than 600 million people globally live with painful osteoarthritis, a number that continues to rise as populations age. While opioid-based treatments have historically filled parts of that gap, their risks have reshaped global expectations for what pain management should look like. The future being explored here is not just about stronger painkillers. It is about safer ones that don’t create new public health crises in the process.
Osteoarthritis is often seen as a condition of aging – something inevitable, mechanical, almost accepted. That’s now changing. Longevity science is increasingly asking a different question: what if aging-related decline isn’t just something to manage, but something to intervene in earlier and more precisely?
Seen through that lens, ACD137 is not just a pain compound. It is part of a broader category of research aimed at preserving function, keeping joints, mobility and independence intact for longer.
That may sound ambitious for a preclinical study and it is, but most shifts in medicine start this way, with directional evidence that challenges the default assumptions. For now, ACD137 remains in the preclinical stage. It has not been tested in humans, and many questions remain about safety, durability and real-world efficacy. However, the publication itself signals that NGF-targeted pain research is evolving.
In that evolution lies a more nuanced possibility of not simply eliminating pain, but reshaping how the body’s pain system is tuned as people age. If future studies confirm what this early data suggests, osteoarthritis treatment may shift from managing decline to slowing it and from temporary relief to something closer to long-term preservation.
Main photograph shows (L–R) AlzeCure Pharma CEO Martin Jonsson, and Founder and Head of Discovery, Pontus Forsell. Courtesy of AlzeCure.
[1] https://www.alzecurepharma.se/en/new-scientific-article-published-on-trka-nam-acd137-against-osteoarthritic-pain/
[2] https://www.degruyterbrill.com/document/doi/10.1515/sjpain-2026-0007/html
